首页AIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
收入 | 2.60万 | -25.71% |
经营支出 | 240.50万 | -46.74% |
净收入 | -328.40万 | 11.24% |
净利润率 | -1.26万 | -19.48% |
每股收益 | -1.57 | 77.21% |
息税折旧摊销前利润 | -239.30万 | 45.93% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 240.90万 | -66.55% |
总资产 | 549.40万 | -59.57% |
负债总额 | 1157.10万 | 8.38% |
权益总额 | -607.70万 | — |
发行在外的股份 | 285.31万 | — |
市净率 | -0.66 | — |
资产回报率 | -127.14% | — |
资本回报率 | 163.57% | — |
现金流
现金净变动
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
净收入 | -328.40万 | 11.24% |
来自运营的现金 | -507.90万 | -63.31% |
投资现金 | 29.60万 | -11.38% |
融资现金 | 665.40万 | 4,756.93% |
现金净变动 | 187.10万 | 170.90% |
自由现金流 | -741.39万 | -315.84% |
简介
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
成立时间
1966
员工数量
22
